Brunod Iole, Tosello Barthélémy, Hassid Sophie, Gire Catherine, Thomachot Laurent, Panuel Michel
Pediatric and Neonatal Intensive Care Unit, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Chemin des Bourrely, 13015, Marseille, France.
Department of Neonatology, Hôpital Nord, Assistance Publique des Hôpitaux de Marseille (APHM), Chemin des Bourrely, 13015, Marseille, France.
BMC Pediatr. 2018 Jul 5;18(1):217. doi: 10.1186/s12887-018-1198-4.
Generalized Arterial Calcification of Infancy (GACI) is a heritable ectopic mineralization disorder resulting in diffuse arterial calcifications and/or stenosis, mostly caused by mutations in the ENPP1 gene. Here we present a case report of GACI in a male infant with a new familial mutation of the ENPP1 gene and the clinical outcome after biphosphonates therapy.
The clinical presentation was characterized by a severe early-onset of hypertension refractory to multiple therapy. To investigate this atypical hypertension, a renal Doppler ultra-sonography was performed and diffuse echo-bright arteries were detected; then a low-dose whole-body computed tomography demonstrated extensive arterial calcifications, suggesting GACI. A novel homozygous mutation c.784A > G (p.Ser262Gly) was detected in the ENPP1 gene. The infant was administered four courses of bisphosphonates: arterial calcifications were found to decrease but severe refractory hypertension was persistent. Although GACI can be a rapidly fatal illness and frequently results in death in infancy, the patient was 24 months of age at the time of writing this report.
Three points of interest: the first one is to remind clinicians of this rare and atypical etiology in neonates with severe hypertension and in fetuses with cardiomyopathy and non-immune hydrops fetalis. The second point is the identification of a novel mutation in the ENPP1 gene associated with a clinical presentation of GACI. The third point is the fairly favourable outcome of our patient after bisphosphonates therapy, with calcifications regression but not hypertension.
婴儿全身性动脉钙化(GACI)是一种遗传性异位矿化疾病,可导致弥漫性动脉钙化和/或狭窄,主要由ENPP1基因突变引起。本文报告1例患有ENPP1基因新的家族性突变的男性婴儿GACI病例及双膦酸盐治疗后的临床结果。
临床表现为严重的早发性高血压,多种治疗均无效。为研究这种非典型高血压,进行了肾脏多普勒超声检查,检测到弥漫性回声增强的动脉;随后低剂量全身计算机断层扫描显示广泛的动脉钙化,提示GACI。在ENPP1基因中检测到一个新的纯合突变c.784A>G(p.Ser262Gly)。该婴儿接受了四个疗程的双膦酸盐治疗:发现动脉钙化减少,但严重的难治性高血压持续存在。尽管GACI可能是一种迅速致命的疾病,且常在婴儿期导致死亡,但撰写本报告时该患者已24个月大。
有三点值得关注:第一点是提醒临床医生,对于患有严重高血压的新生儿以及患有心肌病和非免疫性胎儿水肿的胎儿,要注意这种罕见且非典型的病因。第二点是在ENPP1基因中鉴定出一个与GACI临床表现相关的新突变。第三点是我们的患者在接受双膦酸盐治疗后取得了相当不错的结果,钙化有所消退,但高血压未改善。